enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Merck's Keytruda gets FDA nod for expanded use in lung cancer

   www.aol.com/news/mercks-keytruda-gets-u-fdas...

   The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients. The U.S. drugmaker is ...

3. Merck's Keytruda sets new 5-year survival standard for ... - AOL

   www.aol.com/news/mercks-keytruda-sets-5-survival...

   Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a ...

4. Pembrolizumab - Wikipedia

   en.wikipedia.org/wiki/Pembrolizumab

   Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...

5. Cancer Treatment Centers of America - Wikipedia

   en.wikipedia.org/wiki/Cancer_Treatment_Centers...

   Cancer Treatment Centers of America (CTCA) was founded in 1988 by Richard J. Stephenson following the death of his mother, Mary Brown Stephenson, who died from lung cancer. [3] Stephenson purchased the American International Hospital in Zion, Illinois , in 1988 and expanded the hospital to include a radiation center, the Mary Brown Stephenson ...

6. Merck's Keytruda Improves 5-Year Survival in Lung Cancer - AOL

   www.aol.com/news/mercks-keytruda-improves-5...

   Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates

7. Merck's Keytruda As Adjuvant Treatment Improves Disease ... - AOL

   www.aol.com/news/mercks-keytruda-adjuvant...

   Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless ...

8. Merck stops testing combo drug for lung cancer - AOL

   www.aol.com/news/merck-stops-testing-combo-drug...

   (Reuters) -Merck said on Thursday it had discontinued a trial testing a combination immunotherapy treatment in patients with a type of lung cancer after an interim analysis showed the drug was ...

9. Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion - AOL

   www.aol.com/news/merck-gets-fda-nod-keytruda...

   Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.